SILO PHARMA GRANTED EUROPEAN PATENT FOR INNOVATIVE PTSD PREVENTION TREATMENT
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy SILO?
Source: moomoo
- Patent Approval: Silo Pharma has received a European patent allowance for its licensed novel PTSD prevention therapy.
- Therapeutic Focus: The therapy aims to address post-traumatic stress disorder (PTSD) through innovative treatment methods.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SILO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SILO
About SILO
Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SILO PHARMA GRANTED EUROPEAN PATENT FOR INNOVATIVE PTSD PREVENTION TREATMENT
- Patent Approval: Silo Pharma has received a European patent allowance for its licensed novel PTSD prevention therapy.
- Therapeutic Focus: The therapy aims to address post-traumatic stress disorder (PTSD) through innovative treatment methods.
See More
Silo Pharma Secures EPO Patent Approval for 5-HT4 Therapy
- Patent Approval Milestone: Silo Pharma has received a communication from the European Patent Office (EPO) indicating its intent to grant a patent for the use of 5-HT4 receptor agonists in preventing stress-related disorders, marking a significant advancement in the company's global intellectual property position and expected to enhance its strategic positioning in major European markets.
- Innovative Treatment Approach: The patent covers methods for preventing stress-induced fear and depressive-like behaviors using selected 5-HT4 receptor agonists, representing a proactive treatment strategy that targets pathways associated with stress resilience, potentially transforming the treatment landscape for stress-related disorders and addressing urgent market needs.
- Significant Market Potential: CEO Eric Weisblum emphasized that stress-related disorders represent a massive and underserved market, and the patent's approval will facilitate the advancement of the company's pipeline in this area, thereby enhancing its competitive edge.
- Global Strategic Expansion: The company is evaluating Unitary Patent protection and key national validations to maximize geographic coverage and long-term value, further solidifying its leadership position in the global mental health and stress-related treatment sectors.
See More
Silo Pharma Secures Patent for PTSD Therapy
- Patent Grant: Silo Pharma has been awarded a patent for the application titled 'Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress,' further solidifying the company's position in the mental health market, which is considered a 'massive and underserved market.'
- Market Reaction: Following the European Patent Office's indication to grant the patent, Silo Pharma's shares surged over 85% in premarket trading on Tuesday, reflecting strong investor confidence and market anticipation for the new therapy.
- Innovative Therapy: This therapy differs from traditional PTSD treatments by focusing on enhancing stress resilience rather than managing symptoms post-trauma, indicating a strategic shift in the company's treatment approach that may attract more attention and investment.
- Global IP Expansion: Silo Pharma described the patent grant as a 'high-value milestone' that will strengthen its global intellectual property position, aiding the company's efforts to maximize geographic coverage and long-term value.
See More
Silo Pharma Secures European Patent for Stress Disorder Prevention
- Patent Progress: Silo Pharma has received a patent allowance from the European Patent Office for an innovative approach to preventing stress-related disorders, marking a significant milestone in the biopharmaceutical sector that is expected to enhance its intellectual property portfolio and market competitiveness.
- Therapeutic Potential: The patent focuses on preventing stress-induced fear and depressive behaviors through the 5-HT4 receptor pathway, representing a shift from symptom management to prevention, which could open new avenues in mental health treatment.
- Diversified Pipeline: Silo Pharma is advancing several programs, including SPC-15 for PTSD, SP-26 for fibromyalgia, and SPC-14 for neuroinflammation, with multiple data releases expected in 2026, showcasing the company's extensive commitment to mental health.
- Broad Market Outlook: With increasing global attention on mental health, Silo Pharma's patent allowance positions it to lead in CNS therapeutics, potentially reshaping how clinicians and patients approach the management of psychiatric disorders.
See More
Silo Pharma Authorizes $1 Million Share Repurchase Program
- Share Repurchase Program: Silo Pharma's board has authorized a share repurchase program of up to $1 million, which is expected to enhance investor confidence and potentially boost stock prices, thereby improving the company's market performance in the biopharmaceutical sector.
- Stock Price Surge: Following the announcement, SILO shares rose 32.75% to $0.37 in premarket trading, indicating positive market sentiment regarding the company's future, particularly in its drug development efforts.
- R&D Progress: The company plans to submit an IND application for SPC-15 to the FDA this year as a treatment for PTSD and stress-induced anxiety disorders, which, if approved, will initiate the first-in-human trial and further advance the commercialization of its product pipeline.
- Financial Performance: For the quarter ended September 30, 2025, Silo Pharma reported a wider net loss of $1.20 million, or $0.19 per share, while license revenue remained flat, highlighting the need for cost control measures to achieve sustainable growth.
See More
Keysight Technologies Quarterly Earnings Beat Estimates
- Strong Earnings Performance: Keysight Technologies reported earnings per share of $2.17, exceeding Wall Street's expectation of $2, demonstrating robust profitability that boosts investor confidence.
- Significant Revenue Growth: The quarterly revenue reached $1.6 billion, surpassing the analyst consensus of $1.54 billion, indicating successful business expansion and strong market demand, further solidifying its market position.
- Stock Price Surge: Keysight's shares jumped 16.8% to $286.03 in pre-market trading, reflecting a positive investor reaction to the company's financial performance, which may attract more investor interest.
- Market Dynamics Impact: Keysight's strong results could influence the performance of other related stocks, particularly in the technology and electronics sectors, signaling an overall improvement in market sentiment.
See More
SILO PHARMA GRANTED EUROPEAN PATENT FOR INNOVATIVE PTSD PREVENTION TREATMENT
- Patent Approval: Silo Pharma has received a European patent allowance for its licensed novel PTSD prevention therapy.
- Therapeutic Focus: The therapy aims to address post-traumatic stress disorder (PTSD) through innovative treatment methods.
See More
Silo Pharma Secures EPO Patent Approval for 5-HT4 Therapy
- Patent Approval Milestone: Silo Pharma has received a communication from the European Patent Office (EPO) indicating its intent to grant a patent for the use of 5-HT4 receptor agonists in preventing stress-related disorders, marking a significant advancement in the company's global intellectual property position and expected to enhance its strategic positioning in major European markets.
- Innovative Treatment Approach: The patent covers methods for preventing stress-induced fear and depressive-like behaviors using selected 5-HT4 receptor agonists, representing a proactive treatment strategy that targets pathways associated with stress resilience, potentially transforming the treatment landscape for stress-related disorders and addressing urgent market needs.
- Significant Market Potential: CEO Eric Weisblum emphasized that stress-related disorders represent a massive and underserved market, and the patent's approval will facilitate the advancement of the company's pipeline in this area, thereby enhancing its competitive edge.
- Global Strategic Expansion: The company is evaluating Unitary Patent protection and key national validations to maximize geographic coverage and long-term value, further solidifying its leadership position in the global mental health and stress-related treatment sectors.
See More
Silo Pharma Secures Patent for PTSD Therapy
- Patent Grant: Silo Pharma has been awarded a patent for the application titled 'Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress,' further solidifying the company's position in the mental health market, which is considered a 'massive and underserved market.'
- Market Reaction: Following the European Patent Office's indication to grant the patent, Silo Pharma's shares surged over 85% in premarket trading on Tuesday, reflecting strong investor confidence and market anticipation for the new therapy.
- Innovative Therapy: This therapy differs from traditional PTSD treatments by focusing on enhancing stress resilience rather than managing symptoms post-trauma, indicating a strategic shift in the company's treatment approach that may attract more attention and investment.
- Global IP Expansion: Silo Pharma described the patent grant as a 'high-value milestone' that will strengthen its global intellectual property position, aiding the company's efforts to maximize geographic coverage and long-term value.
See More
Silo Pharma Secures European Patent for Stress Disorder Prevention
- Patent Progress: Silo Pharma has received a patent allowance from the European Patent Office for an innovative approach to preventing stress-related disorders, marking a significant milestone in the biopharmaceutical sector that is expected to enhance its intellectual property portfolio and market competitiveness.
- Therapeutic Potential: The patent focuses on preventing stress-induced fear and depressive behaviors through the 5-HT4 receptor pathway, representing a shift from symptom management to prevention, which could open new avenues in mental health treatment.
- Diversified Pipeline: Silo Pharma is advancing several programs, including SPC-15 for PTSD, SP-26 for fibromyalgia, and SPC-14 for neuroinflammation, with multiple data releases expected in 2026, showcasing the company's extensive commitment to mental health.
- Broad Market Outlook: With increasing global attention on mental health, Silo Pharma's patent allowance positions it to lead in CNS therapeutics, potentially reshaping how clinicians and patients approach the management of psychiatric disorders.
See More
Silo Pharma Authorizes $1 Million Share Repurchase Program
- Share Repurchase Program: Silo Pharma's board has authorized a share repurchase program of up to $1 million, which is expected to enhance investor confidence and potentially boost stock prices, thereby improving the company's market performance in the biopharmaceutical sector.
- Stock Price Surge: Following the announcement, SILO shares rose 32.75% to $0.37 in premarket trading, indicating positive market sentiment regarding the company's future, particularly in its drug development efforts.
- R&D Progress: The company plans to submit an IND application for SPC-15 to the FDA this year as a treatment for PTSD and stress-induced anxiety disorders, which, if approved, will initiate the first-in-human trial and further advance the commercialization of its product pipeline.
- Financial Performance: For the quarter ended September 30, 2025, Silo Pharma reported a wider net loss of $1.20 million, or $0.19 per share, while license revenue remained flat, highlighting the need for cost control measures to achieve sustainable growth.
See More
Keysight Technologies Quarterly Earnings Beat Estimates
- Strong Earnings Performance: Keysight Technologies reported earnings per share of $2.17, exceeding Wall Street's expectation of $2, demonstrating robust profitability that boosts investor confidence.
- Significant Revenue Growth: The quarterly revenue reached $1.6 billion, surpassing the analyst consensus of $1.54 billion, indicating successful business expansion and strong market demand, further solidifying its market position.
- Stock Price Surge: Keysight's shares jumped 16.8% to $286.03 in pre-market trading, reflecting a positive investor reaction to the company's financial performance, which may attract more investor interest.
- Market Dynamics Impact: Keysight's strong results could influence the performance of other related stocks, particularly in the technology and electronics sectors, signaling an overall improvement in market sentiment.
See More
